Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | POLQ | O75417 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | ASPH | Q12797 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19366821 | 0.88 | HSP90AA1 (0.33) | AGBL2POLBHSP90AA1 | |
| SCHEMBL19370438 | 0.88 | AGBL2 (0.31) | AGBL2POLBHSP90AA1 | |
| SCHEMBL16404975 | 0.88 | AGBL2 (0.43) | AGBL2POLBPKMPOLQHPGD | |
| SCHEMBL13688735 | 0.85 | HSP90AA1 (0.36) | POLBHSP90AA1 | |
| SCHEMBL24662463 | 0.85 | CYP11B2 (0.38) | AGBL2POLBPKMPOLQASPH | |
| SCHEMBL20457089 | 0.84 | AGBL2 (0.41) | AGBL2POLBPKMPOLQHPGD | |
| SCHEMBL19628512 | 0.80 | POLB (0.33) | AGBL2POLBPKMPOLQKIF11 | |
| SCHEMBL10197339 | 0.78 | HSP90AA1 (0.36) | AGBL2POLBPKMPOLQHPGD | |
| SCHEMBL19370437 | 0.78 | PIK3CD (0.46) | POLBPKMPOLQ | |
| SCHEMBL10201441 | 0.78 | MAP3K12 (0.42) | HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040804-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10040804-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-9603819-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| US-20150174089-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174089-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, GABRB1, GABRE | AGBL2 1843/4885POLB 3310/4885PKM 3459/4885 |
| US-10040804-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | AGBL2 1515/4885POLB 4760/4885PKM 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.